This is the latest advice from the Australian Rheumatology Association about the timing, safety and efficacy of COVID-19 vaccines for rheumatology patients.
A global shortage of tocilizumab (Actemra®) is forcing some patients with inflammatory conditions to urgently review their treatment with their treating doctor.
What will the current COVID-19 vaccine candidates mean for Australians with autoimmune conditions? Can we take them? When will we get them?
Ixekizumab (Taltz®) is a new treatment option for Australians with ankylosing spondylitis - a chronic form of arthritis that affects the spine and pelvis.
It can be a big adjustment to give yourself injections. These tips can make the process less scary.
Do you use a biologic medication for your inflammatory arthritis? Do you know about biosimilars? Discover the basics as part of Biosimilar Awareness Week.
Axial spondyloarthritis (including ankylosing spondylitis) is a common form of arthritis, yet most Australians haven’t heard of it. CreakyJoints Australia would like to help change that.
Upadacitinib (Rinvoq®) is a new treatment option now available for adults with moderate to severe RA who can't tolerate methotrexate or don't respond sufficiently to it.
What should you do if you can’t access Plaquenil? Are you at risk of COVID-19 exposure if you have a biologic infusion in a hospital? We’ve got the answers you’ve been seeking.
Are you an Australian with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn’s Disease or ulcerative colitis?